Newsletter : Pompe Disease Newsletter



An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also called Glycogen Storage disease type II, Pompe disease affects around 5,000 to 10,000 people worldwide, with an equal preponderance in Males and females. DelveInsight's newsletter series brings to light an overview of Pompe disease, underlying cause, Etiology, Symptoms, Market and Epidemiology. Top companies involved :
Tetra Therapeutics, , , Confluence Pharmaceuticals, and Neuren Pharmaceuticals. Have a Copy our Newsletter : https://www.delveinsight.com/whitepaper-newsletter/pompe-disease hashtag

Comments

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

Cervical Intraepithelial Neoplasia Market and Epidemiology 2032 by DelveInsight

The Need And The Importance Of The Healthcare Reports for the Pharma Companies